Home > Boards > US Listed > Cannabis >

Zynerba Pharmaceuticals (ZYNE)

ZYNE RSS Feed
Add ZYNE Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 7/13/2021 11:19:40 PM - Followers: 101 - Board type: Free - Posts Today: 0


Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome. The Company's ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear that is designed to provide controlled drug delivery with once- or twice-daily dosing. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The Company intends to test the ZYN001 patch for application to the arm, back and thigh. The Company intends to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.

Investor Relations

Corporate Profile

Zynerba (NASDAQ: ZYNE) is pioneering the development of patent-protected, next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its two lead product candidates in development include ZYN002 and ZYN001, which are being evaluated in five indications. ZYN002 is the first and only synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In June 2016, the company initiated the STAR 1 Phase 2 clinical trial in refractory epilepsy patients and in August 2016, initiated the STOP Phase 2 clinical trial in patients with osteoarthritis of the knee. A Phase 2 clinical trial in patients with Fragile X syndrome will be initiated in the second half of 2016. 

ZYN001, a prodrug of THC that enables transdermal delivery through the skin and circulatory system via a patch, is in preclinical development. A Phase 1 clinical trial is planned in the first half of 2017.

In August 2015, Zynerba completed an initial public offering, raising net proceeds of $42.1 million. As of June 30, 2016, cash and cash equivalents totaled $32.1 million, which is projected to fund five Phase 2 clinical trials through 2017.





Zynerba Pharmaceuticals, Inc., (Nasdaq: ZYNE) announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. In addition, Zynerba has granted the underwriters an option to purchase up to 450,000 additional shares of common stock at the public offering price, less the underwriting discount. Zynerba's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the symbol "ZYNE" on August 5, 2015.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, and Canaccord Genuity Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. This offering is being made only by means of a prospectus.



Extremely low float:

Fundamentals

A table providing the fundamentals of the stock
EPS (TTM) 9/30/2016 | -2.47
P/E Ratio 9/30/2016 | --
Market Cap Micro Cap | 146M
Shares Outstanding 9.95M
Float 7.2M

 

ZYNE
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ZYNE News: Current Report Filing (8-k) 07/14/2021 07:12:14 AM
ZYNE News: Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Virtual Healthcare Conference 07/07/2021 07:30:00 AM
ZYNE News: Current Report Filing (8-k) 06/30/2021 07:07:28 AM
ZYNE News: Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting 06/30/2021 07:00:00 AM
ZYNE News: Additional Proxy Soliciting Materials (definitive) (defa14a) 06/11/2021 04:06:24 PM
PostSubject
#2654   On May 14, settled the securities class action jgrabar 06/30/21 09:50:04 AM
#2653   Zynerba could not meet quorum at a recent Jdanger 2 06/16/21 01:26:52 PM
#2652   zyne may just be that wild card you were RHF469usa 05/07/21 03:17:31 PM
#2651   Whatz up w this co ? Power-Fade 04/17/21 10:44:45 PM
#2650   $zyne $4.62 v -0.14 (-2.94%) Taurus69 03/28/21 08:11:18 PM
#2649   When are we going for a run!! Jay_Holg 03/23/21 01:28:30 PM
#2648   Shorts on this like flies on... Jdanger 2 03/16/21 03:51:59 PM
#2647   $zyne $4.57 ^ 0.11 (2.47%) Taurus69 02/27/21 05:44:28 AM
#2646   Buy buy buy. $zyne $sndl & $chnc mclaxer5155 02/11/21 03:10:28 PM
#2645   * * $ZYNE Video Chart 02-10-2021 * * ClayTrader 02/10/21 06:02:16 PM
#2644   $zyne $5.15 ^ 0.64 (14.19%) Taurus69 02/07/21 01:45:11 PM
#2643   * * $ZYNE Video Chart 02-05-2021 * * ClayTrader 02/05/21 05:27:42 PM
#2642   * * $ZYNE Video Chart 02-03-2021 * * ClayTrader 02/03/21 05:35:08 PM
#2641   Blessings on ZYNE today. And my God will meet Bag_man 02/03/21 09:49:55 AM
#2640   $zyne $3.6 v -0.02 (-0.55%) Taurus69 01/21/21 11:18:18 PM
#2639   $zyne $3.45 ^ 0.01 (0.29%) Taurus69 12/22/20 10:37:54 PM
#2638   The market absofreakinlutely hates this stock. nunaka 12/17/20 04:09:57 PM
#2637   Anyone listen to the CC this morning? Jdanger 2 12/17/20 02:20:37 PM
#2636   Are you suggesting a hoax? Thanks!!! Termite7 12/11/20 10:36:49 AM
#2635   https://twitter.com/zynerbapharma/status/1334903255424520194?s=21 Poster presen Stockfun1 12/04/20 11:17:03 PM
#2634   Makes sense. Press Release was found under Stockfun1 12/03/20 02:39:06 AM
#2633   This is not Zynerba Another company Similar ticker, Ihub58 12/02/20 08:48:18 PM
#2632   Good read.......no,I WAS NOT AWARE. dhbuzz 12/02/20 08:33:34 PM
#2631   dhbuzz, not sure if you saw the Stockfun1 12/02/20 06:00:28 PM
#2630   lol....no sheet man.......... dhbuzz 11/30/20 06:58:12 PM
#2629   $zyne $4.61 ^ 0.03 (0.66%) Taurus69 11/28/20 02:50:51 PM
#2628   http://ir.zynerba.com/sec-filings/sec-filing/sc-13ga/0001213900-20-037198 steadykickin 11/16/20 12:16:12 PM
#2627   LOL.. dhbuzz 11/12/20 07:46:50 PM
#2626   $zyne $3.78 ? 0.0 (0.00%) Taurus69 11/12/20 05:14:51 AM
#2625   Nice move in Germany Friday for ZYNE ON dhbuzz 11/07/20 10:17:29 AM
#2624   I continue to hold, positive news on FMFX dhbuzz 11/07/20 09:48:27 AM
#2623   Still here. Still a great price to load up Jdanger 2 11/06/20 02:53:09 PM
#2622   . dhbuzz 11/06/20 01:39:19 AM
#2621   $zyne $3.4 v -0.03 (-0.87%) Taurus69 10/31/20 02:44:17 PM
#2620   I would think there should be word from Stockfun1 10/29/20 08:34:01 AM
#2619   We wait,and we watch. dhbuzz 10/28/20 10:59:27 PM
#2618   https://www.tipranks.com/stocks/zyne/forecast dhbuzz 10/27/20 10:58:37 AM
#2617   https://finance.yahoo.com/news/canaccord-predicts-over-100-rally-150126313.html dhbuzz 10/27/20 10:49:38 AM
#2616   Short interest only 19.9%. Anyone understand what’s going Stockfun1 10/20/20 11:30:50 AM
#2615   . dhbuzz 10/17/20 03:07:31 AM
#2614   NEWS: $ZYNE Zynerba Pharmaceuticals Presents Data Supporting FMR1 whytestocks 10/15/20 08:15:31 PM
#2613   JUST IN: $ZYNE New Data Describing Statistically Significant whytestocks 10/15/20 03:30:26 PM
#2612   Amazing results resented at the conference today. ZYNE Jdanger 2 10/15/20 03:13:01 PM
#2611   dhbuzz 10/08/20 06:07:42 AM
#2610   $zyne $3.41 ^ 0.04 (1.19%) Taurus69 10/06/20 11:12:37 PM
#2609   “Zynerba is committed to developing Zygel™ CBD gel dhbuzz 09/19/20 12:19:26 PM
#2608   https://byebyedoctor.com/digeorge-syndrome/ dhbuzz 09/19/20 11:59:42 AM
#2607   ZANERBA is about to get some serious dhbuzz 09/19/20 11:46:07 AM
#2606   Hey Lumpy dhbuzz 09/18/20 09:01:34 AM
#2605   https://seekingalpha.com/article/4375033-making-case-for-zynerba-pharmaceuticals Stockfun1 09/18/20 08:29:49 AM
PostSubject
Consent Preferences